In a report released today, Raju Prasad from William Blair maintained a Buy rating on Loxo Oncology (NASDAQ: LOXO). The company’s shares closed on Friday at $159.60.
According to TipRanks.com, Prasad is a 3-star analyst with an average return of 3.8% and a 33.3% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Audentes Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Loxo Oncology with a $199.14 average price target, which is a 24.8% upside from current levels. In a report issued on September 24, Leerink Partners also initiated coverage with a Buy rating on the stock with a $205 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $208.95 and a one-year low of $71.45. Currently, Loxo Oncology has an average volume of 323.4K.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT.
